Novavax isn't targeting the KP.2 variant, but the JN.1 lineage, which provides strong immune support for KP.2 and KP.3 variant lines, including the more recent mutations along the JN.1 lineage. Novavax made the decision and and were already in production "at risk" prior to the 16-member FDA advisory panel unanimously recommended all vaccine makers target JN.1 as this was the "trunk of the tree" and would be the best solution for the 2024-25 vaccine season because the mutations were occurring faster than in previous seasons, and targeting a specific variant was riskier. Peter Marks took it upon himself to override the panel recommendation and once again try to leave Novavax at a disadvantage.
Notice how all the media stories about the mRNA vaccine approvals imply that Novavax will not be as effective as mRNA because they targeted KP.2 and Novavax targeted JN.1. The reality is the Novavax vaccine is superior because of it's Matrix M adjuvant and will prove more effective with higher antibody levels and fewer side effects than the mRNA vaccines of the competitors. Peter Marks' "freshest milk" analogy was pathetic, because vaccine formulation strategy is magnitudes more complex than shopping for milk and many more factors are involved that simply production date.
News 
Market Data 
Discover 
AI
